Strong patent protection has always been a cornerstone of the biotech industry — and table stakes in a VC deal. But inter partes review has significantly changed the game in the last 5 years. Enter Scott Kamholz. Scott is once, twice, three times a doctor: Medicinae, Philosophiae, and Juris. He went from partner at a law firm, to patent judge, became a foremost expert in inter partes review, and then back to private practice at Covington & Burling with 250 IPR cases under his belt. Whether you’re a baby biotech with a patent license as your only asset or large pharma with marketed products to worry about, he is a good person to know. Scott is a great legal mind, but he cannot give a straight answer to a yes or no question.
Strong patent protection has always been a cornerstone of the biotech industry — and table stakes in a VC deal. But inter partes review has significantly changed the game in the last 5 years. Enter Scott Kamholz. Scott is once, twice, three times a doctor: Medicinae, Philosophiae, and Juris. He went from partner at a […]
Strong patent protection has always been a cornerstone of the biotech industry — and table stakes in a VC deal. But inter partes review has significantly changed the game in the last 5 years.
Enter Scott Kamholz. Scott is once, twice, three times a doctor: Medicinae, Philosophiae, and Juris.
He went from partner at a law firm, to patent judge, became a foremost expert in inter partes review, and then back to private practice at Covington & Burling with 250 IPR cases under his belt.
Whether you’re a baby biotech with a patent license as your only asset or large pharma with marketed products to worry about, he is a good person to know.
Scott is a great legal mind, but he cannot give a straight answer to a yes or no question.